| Stephen Pollet, MD | |
|
7373 Perkins Rd, Baton Rouge, LA 70808-4326 | |
| (225) 769-4044 | |
| Not Available |
| Full Name | Stephen Pollet |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 44 Years |
| Location | 7373 Perkins Rd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265453955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 015725 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baton Rouge Clinic, A Medical Corporation | 1254317001 | 218 |
News Archive
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
Reuters reports on rampant Medicare fraud and the development of new technologies that can be used to fight it.
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 6 days ago
| Entity Name | Baton Rouge Clinic, A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871546911 PECOS PAC ID: 1254317001 Enrollment ID: O20040624000911 |
News Archive
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
Reuters reports on rampant Medicare fraud and the development of new technologies that can be used to fight it.
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 6 days ago
| Entity Name | Lsuhn Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992975775 PECOS PAC ID: 0446337802 Enrollment ID: O20080409000372 |
News Archive
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
Reuters reports on rampant Medicare fraud and the development of new technologies that can be used to fight it.
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Pollet, MD 7373 Perkins Rd, Baton Rouge, LA 70808-4326 Ph: (225) 769-4044 | Stephen Pollet, MD 7373 Perkins Rd, Baton Rouge, LA 70808-4326 Ph: (225) 769-4044 |
News Archive
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
A study by Nanyang Technological University, Singapore has found that as the type of COVID-19 misinformation rectified by Singapore's mainstream news media evolved over the course of the pandemic, the role played by the media in debunking those myths became increasingly important to citizens in the nation's fight to manage the outbreak.
Reuters reports on rampant Medicare fraud and the development of new technologies that can be used to fight it.
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 6 days ago
Dr. Jennifer L Rippon, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7777 Hennessy Blvd Ste 409, Baton Rouge, LA 70808 Phone: 225-765-5864 Fax: 225-765-2013 | |
Gregory Fusilier, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 9103 Jefferson Hwy, Baton Rouge, LA 70809 Phone: 225-927-1190 Fax: 225-927-0988 | |
Dr. Yolanda Maria O'rourke, Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 7968 Essen Park, Baton Rouge, LA 70809 Phone: 225-761-6700 Fax: 225-761-6760 | |
Patricia D. Whatley, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Attn: Dee / Administration, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Frederick Cerise, Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3810 W Lakeshore Dr, Baton Rouge, LA 70808 Phone: 225-578-8886 | |
Dr. Jon Richard Jackson, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5000 Hennessy Blvd, Baton Rouge, LA 70808 Phone: 225-765-4050 Fax: 225-765-4046 | |
Richard Frank Burroughs, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: Earl K. Long Hospital, Lsu Unit, 5825 Airline Highway, Baton Rouge, LA 70805 Phone: 225-358-3938 |